Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Phase 1

Terminated

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Secondary Myelofibrosis

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: Treg cell infusion
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-09-15

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT00376519

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: peripheral blood lymphocyte therapy
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: thiotepa
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2006-09-15

Last Posted Date: 2019-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00376480

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 3 locations

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total body irradiation
Other: Natural killer cell infusion
Biological: Interleukin-2

First Posted Date: 2006-09-15

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 6

Registration Number: NCT00376805

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Therapy for Chronic Cold Agglutinin Disease

Phase 2

Completed

Conditions: Cold Agglutinin Disease

First Posted Date: 2006-09-08

Last Posted Date: 2010-06-22

Lead Sponsor: University of Bergen

Target Recruit Count: 30

Registration Number: NCT00373594

Locations: 🇳🇴
Haugesund Hospital, Haugesund, Norway
🇷🇺
BMT Clinic, St Petersburg Pavlov State Medical University, St Petersburg, Russian Federation
🇳🇴
Haukeland University Hospital, Bergen, Norway

and more 3 locations

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Phase 1

Completed

Conditions: Breast Cancer
Lymphoma
Leukemia
Myelodysplastic Syndromes
Kidney Cancer
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-08-17

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 148

Registration Number: NCT00365287

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Phase 4

Completed

Conditions: Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia, Lymphocytic
Myeloma
Lymphoma

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2006-08-07

Last Posted Date: 2017-03-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 72

Registration Number: NCT00361140

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Phase 2

Terminated

Conditions: Severe Aplastic Anemia
Genetic Disorder
Immunodeficiency Syndrome

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2006-08-01

Last Posted Date: 2021-01-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00358657

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Phase 2

Active, not recruiting

Conditions: Recurrent Childhood Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts in Transformation
Refractory Anemia
De Novo Myelodysplastic Syndrome
Secondary Myelodysplastic Syndrome
Childhood Myelodysplastic Syndrome
Leukemia
Myelodysplastic Syndromes
Secondary Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts

Interventions: Biological: filgrastim
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: melphalan
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-07-27

Last Posted Date: 2024-08-22

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 33

Registration Number: NCT00357565

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: aldesleukin
Biological: filgrastim
Biological: natural killer cell (NK) therapy
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: mycophenolate mofetil
Procedure: Umbilical Cord Blood Transplantation (UCBT)
Radiation: Total body irradiation (TBI)

First Posted Date: 2006-07-20

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT00354172

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

TBI Dose De-escalation for Fanconi Anemia

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Total Body Irradiation
Procedure: Bone Marrow Transplantation
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2006-07-17

Last Posted Date: 2021-11-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 83

Registration Number: NCT00352976

Locations: 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy